{
  "id": 7280812,
  "title": "AstraZeneca: SERENA-4 Trial Of Etcamah Palbociclib Combination Fails To Meet Primary Objective",
  "url": "https://urgent.news/2026/09/14/astrazeneca-serena-4-trial-of-etcamah-palbociclib-combination-fails",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-14T06:34:03.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/astrazeneca-serena-4-trial-etcamah-palbociclib-combination-fails-meet-primary-objective"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the SERENA-4 Phase III trial of Etcamah or camizestrant in combination with palbociclib did not meet the primary endpoint of progression-free survival in upfront 1st-line advanced ER-positive breast cancer. However a numer",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "AstraZeneca’s Etcamah trial misses primary endpoint",
        "url": "https://urgent.news/2026/09/14/astrazenecas-etcamah-trial-misses-primary-endpoint",
        "published": "2026-09-14T06:14:38.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}